ライフサイエンスコーパス: ADL

1 ADL difficulties increased by 0.22 standard deviations (

2 ADL experienced three major development stages: slower e

3 ADL impairment was associated with an increased risk of

4 ADL should be sequentially evaluated early during treatm

5 covered to premorbid level (difference, 0.09 ADL; 95% CI, -0.27-0.44), but stroke patients admitted t

6 ance, or needing assistance to perform >or=1 ADL task.

7 s) disability, defined as dependence in >/=3 ADLs for 2 consecutive annual interviews or for 1 interv

8 ; number of dependent ADLs at discharge (1-4 ADLs, 2 points; all 5 ADLs, 5 points); congestive heart

9 ally frail, or severely disabled (ie, in 3-4 ADLs) at onset were less likely to recover than those wh

10 ecovered (ie, regained independence in all 4 ADLs) within 12 months of their initial disability episo

11 1-3.81; IADL impairment: OR 3.12, 2.20-4.41; ADL impairment: OR 1.58, 1.11-2.24).

12 ADLs at discharge (1-4 ADLs, 2 points; all 5 ADLs, 5 points); congestive heart failure (2 points); ca

13 1.5-7.2) and recover ADLs (difference, 0.63 ADL; 95% CI, 0.20-1.07).

14 as performed (P < .01), a difference of 0.67 ADL abilities retained by the GC group compared with the

15 5% CI 1.3-2.8; p = 0.001, p for trend across ADL categories = 0.001) after controlling for a broad ra

16 In both groups, ADCS ADL scores declined over 24 months.

17 At the primary end point of 24 months, ADCS ADL scores did not differ between groups (mean differenc

18 Group Activities of Daily Living Scale (ADCS ADL); performance-based measures included the Short Phys

19 Group Activities of Daily Living Scale (ADCS ADL); performance-based measures included the Short Phys

20 % CI, -0.9 to 1.1; P = .86 and -0.5 for ADCS-ADL; 95% CI, -1.9 to 0.9; P = .48) using an intent-to-tr

21 .43, -2.06 to 1.20, p=0.9323; change in ADCS-ADL score compared with control [-8.22, 95% CI -9.63 to

22 y-Activities of Daily Living Inventory (ADCS-ADL) scales from baseline assessed at week 65 in the mod

23 y-Activities of Daily Living Inventory; ADCS-ADL), and model the relationship between cognitive measu

24 bo group in activities of daily living (ADCS-ADL difference in slope 3.98 [95% CI 0.33 to 7.62] point

25 ative Study/Activities of Daily Living (ADCS-ADL) Inventory score (range, 0-78).

26 ative Study-Activities of Daily Living (ADCS-ADL) scale, on which scores range from 0 to 78 and highe

27 ive Studies-activities of daily living (ADCS-ADL) scale.

28 e per day had no significant effects on ADCS-ADL and ADAS-cog and had a negative effect on CDR-sb (-5

29 Study activities of daily living scale (ADCS-ADL), and the clinical dementia rating sum of boxes (CDR

30 Study-Activities of Daily Living scale (ADCS-ADL; range, 0 to 78, with lower scores indicating worse

31 to tarenflurbil in the ADAS-cog and the ADCS-ADL (p>or=0.10); therefore, these groups were analysed s

32 w significantly greater declines on the ADCS-ADL or Wechsler Memory Scale.

33 to 0.5; P=0.24) and -0.4 points for the ADCS-ADL score (95% CI, -2.3 to 1.4; P=0.64) in EXPEDITION 1

34 The ADCS-ADL scores also worsened in all groups (mean change at w

35 disease were assessed on the UPSA, the ADCS-ADL, and a battery of neurocognitive tests.

36 impairments on the UPSA but not on the ADCS-ADL.

37 an (SD) follow-up of 2.27 (1.22) years, ADCS-ADL Inventory scores declined by 3.15 units (95% CI, 0.9

38 ations in activities of daily living (ADLs) (ADLs and instrumental ADLs), emergency department visits

39 On the advanced ADL, 58% of patients reported difficulty with errands, 6

40 n index, the odds ratio for the effect of an ADL score of less than 12 of 15 on mortality is 1.83 (95

41 MRS scores (p<0.001), mobility (p<0.001) and ADL (p=0.002) following inpatient treatment.

42 ]), verbal fluency (-0.34 words [0.07]), and ADL (0.64 points [0.04]) during the first 25 years of di

43 The strong relationship of arthritis and ADL disability was partially explained by demographic, h

44 he sensation of noxious chemicals by ASH and ADL neurons; it requires the genes ocr-2 and osm-9, whic

45 J and ASK gustatory neurons, and the ASH and ADL nociceptors, respond to a rise in CO2 with a rise in

46 Ablation of the nociceptive neurons ASH and ADL transforms social animals into solitary feeders.

47 4, acting in the nociceptive neurons ASH and ADL.

48 expression in ASJ, which antagonizes ASI and ADL.

49 G is gap-junctionally coupled to the ASK and ADL pheromone sensors that respectively drive pheromone

50 come in the mother's residence ZIP code, and ADL during the first 90 days after the EDC were factors

51 f transition to combined lower extremity and ADL difficulty first over 72 months.

52 a dose-related response in ICARS, FARS, and ADL scores.

53 ith improvement in neurological function and ADL in patients with FA.

54 investigate the item sequence of 11 IADL and ADL combined into a single scale and functional trajecto

55 We evaluated IADL and ADL data collected at home every 2-3 years over a 24-yea

56 then an overlapping of concomitant IADL and ADL, with bathing and dressing being the earliest ADL lo

57 evant Nagi Disability Scale, IADL Scale, and ADL Scale tasks.

58 %-42.2%; P = .03) between the 2 surveys, and ADL impairment did not change.

59 difficulty in both lower extremity tasks and ADL over 72 months in a cohort of initially high functio

60 Measures of QOL and ADLs (bathing, feeding, and so on) were not independentl

61 t of a gap junction circuit that antagonizes ADL chemical synapses.

62 The prevalence of any ADL limitation was lowest in low-risk people and increas

63 eported having limitations in performing any ADL and 11% in any instrumental ADL only.

64 Ablating the ASH, ADL, or ASK sensory neurons connected to RMG by gap junc

65 ficant deterioration in EDSS but not Barthel ADL Index scores at 1 year, but the difference between t

66 the multivariate model adjusted for baseline ADL and MAX2 index, high baseline GDS (odds ratio [OR],

67 ore likely than sudden death decedents to be ADL dependent (OR, 8.32 [95% CI, 6.46-10.73); cancer dec

68 ine, 697 remained ADL independent, 84 became ADL dependent, 41 died, and 115 were lost to followup 2

69 ion: male sex (1 point); number of dependent ADLs at discharge (1-4 ADLs, 2 points; all 5 ADLs, 5 poi

70 ent and significant predictor for developing ADL disability (adjusted odds ratio 1.5, 95% confidence

71 with bathing and dressing being the earliest ADL losses, and finally total losses for toileting, cont

72 climate and socio-economic data to evaluate ADL and its driving force.

73 ) for SCAFI, 0.93 points per year (0.06) for ADL, and -0.02 points per year (0.004) for EQ-5D-3L.

74 for any outcome, although risk estimates for ADL disability seemed attenuated in African American rel

75 or all covariates, the lowest odds ratio for ADL limitation was for a BMI of 25-<30 (odds ratio = 1.1

76 0.93, 1.30), and the highest odds ratio for ADL limitation was for a BMI of 35 or higher (odds ratio

77 No group differences were found for ADLs or death.

78 ng the Activities of Daily Living-Long Form (ADL-L) and cognitive status with the Cognitive Performan

79 onths postinjury, a decline of nearly 1 full ADL (P < .05).

80 impaired) and moderately dependent function (ADL-L 14.5 +/- 9.4, range 0-28, where 28 = total depende

81 ated with impaired lower-extremity function, ADLs, and IADLs [odds ratio (95% CI): 0.67 (0.47, 0.95),

82 ated with impaired lower-extremity function, ADLs, and IADLs approximately 9 y later, particularly in

83 nts had died, 9% (CI, 8% to 11%) had further ADL decline, 50% (CI, 48% to 52%) had persistent impairm

84 ed during the 14-year follow-up, and 27% had ADL and 43% had IADL disability at baseline.

85 Higher ADL during early gestation was associated with a lower r

86 akes were inversely associated with impaired ADLs and IADLs [odds ratio (95% CI): 0.60 (0.40, 0.90) a

87 In ADL, unc-1(dn) has effects opposite to those of tetanus

88 m-term clinically meaningful improvements in ADL or quality of life in mild to moderate PD.

89 decline correlated with rates of increase in ADL difficulties (r = 0.15, P = 0.05) and IADL difficult

90 fficulties in men and women and increases in ADL difficulties for men only.

91 y disability in instrumental ADLs but not in ADL, or (3) no disability, was assessed from the 2003 he

92 surveyed during 1988-1994, and reductions in ADL impairment observed for nonobese older individuals d

93 sex, increased age, increased dependence in ADLs, and wearing of dentures.

94 le-adjusted odds of having any disability in ADLs versus no disability in people with low risk, any m

95 Impairment in ADLs developed in 22% of participants aged 50 to 64 year

96 ss was significantly related to increases in ADLs for men (b = 0.039, P < 0.01), but not for women (b

97 fair or poor health status or limitations in ADLs or instrumental ADLs, relative to historical trends

98 The high frequency of incident ADL disability attributable to arthritis points to the i

99 omprehensive geriatric assessment, including ADL, Instrumental ADL (IADL), Mini-Nutritional Assessmen

100 dictive model for 90-day mortality including ADL and Braden Scale yielded C statistics of 0.83 (95% C

101 Mortality increased with increasing ADL difficulty; the hazard ratio (95% confidence interva

102 y disabled older persons recover independent ADL function at rates far exceeding those that have been

103 of H2O2 were much more efficient at inducing ADLs than higher concentrations.

104 ctivities of daily living (ADL)/instrumental ADL (IADL) disability, Centers for Epidemiologic Studies

105 tric assessment, including ADL, Instrumental ADL (IADL), Mini-Nutritional Assessment (MNA), Mini-Ment

106 ities of daily living (ADL) and instrumental ADL (IADL).

107 of daily living (ADL) tasks and instrumental ADL.

108 rforming any ADL and 11% in any instrumental ADL only.

109 omen without severe impairment, Instrumental ADL deterioration was significantly less for those livin

110 iving arrangement and change in Instrumental ADL depended on the level of physical impairment.

111 months, as were disabilities in instrumental ADL in 108 (26%) of 422 individuals at 3 months and 87 (

112 alone had a greater decline in Instrumental ADL, especially when compared with those living with non

113 primarily as a deterioration in Instrumental ADL.

114 tal activities of daily living (Instrumental ADL).

115 ties of daily living (ADLs) and instrumental ADLs (IADLs) for which patients needed assistance.

116 ies of daily living (ADLs), and instrumental ADLs (IADLs) self-reported approximately 9 y later in mo

117 ties of daily living (ADLs) and instrumental ADLs (IADLs) were evaluated through survey instruments.

118 The number of ADLs and instrumental ADLs (range, 0-12) that the participant could not perfor

119 f daily living (ADLs) (ADLs and instrumental ADLs), emergency department visits and hospital admissio

120 ties of daily living [ADLs] and instrumental ADLs).

121 Results were similar for instrumental ADLs, in both men and women.

122 of 20 years, and impairment in instrumental ADLs (IADLs), defined similarly.

123 g (ADLs), (2) any disability in instrumental ADLs but not in ADL, or (3) no disability, was assessed

124 tatus or limitations in ADLs or instrumental ADLs, relative to historical trends, were detected.

125 eding personal assistance with 1 or more key ADLs (bathing, dressing, walking, and transferring), was

126 y the intensity of aeolian desertified land (ADL).

127 For each infant, average day length (ADL) was calculated during different cumulative time per

128 we demonstrated that aldehydic DNA lesions (ADLs) were induced in mammalian cells by 10 mM hydrogen

129 at baseline to lower extremity limitations, ADL difficulty, or both 18, 36, and 72 months later.

130 nd impairment in activities of daily living (ADL) (defined as severe or moderate to severe) for adult

131 ility to perform activities of daily living (ADL) (five-point scale) before and after vertebroplasty.

132 f limitations in activities of daily living (ADL) among non-Hispanic white, non-Hispanic black, and H

133 of life measures activities of daily living (ADL) and EQ-5D-3L index.

134 red with several activities of daily living (ADL) and instrumental activities of daily living (IADL)

135 status based on activities of daily living (ADL) and instrumental ADL (IADL).

136 (IADL) and basic Activities of Daily Living (ADL) and trajectories of dependency before death in an e

137 th or decline in activities of daily living (ADL) at six months, relative to baseline.

138 characteristics, activities of daily living (ADL) dependency, comorbid conditions, length of hospital

139 ination, Barthel Activities of Daily Living (ADL) Index of general disability, EDSS, a 0-4 ataxia sca

140 Activity of Daily Living (ADL) Index, pulmonary, endocrine and central nervous sys

141 mless chair) and activities of daily living (ADL) limitations (transferring, eating, and dressing).

142 s who reported any activity of daily living (ADL) or instrumental activity of daily living (IADL) imp

143 fe measures: the activities of daily living (ADL) part of the Friedreich's Ataxia Rating Scale and EQ

144 o Spanish: the 8 activities of daily living (ADL) question of the Modified Health Assessment Question

145 .5 points on the Activities of Daily Living (ADL) scale between the beginning of chemotherapy and the

146 n (MMSE), the HD Activities of Daily Living (ADL) Scale, and a number of demographic variables (CAG n

147 a modified Katz Activities of Daily Living (ADL) scale, three items from the Rosow-Breslau Functiona

148 ) Scale, and the Activities of Daily Living (ADL) Scale.

149 to perform basic activities of daily living (ADL) tasks and instrumental ADL.

150 Disability in activities of daily living (ADL) was identified from report of inability, avoidance,

151 nd self-reported activities of daily living (ADL) were obtained.

152 ilities in basic activities of daily living (ADL) were present in 139 (32%) of 428 patients at 3 mont

153 h limitations in activities of daily living (ADL) were randomized to physiotherapy and occupational t

154 nce status (PS), Activities of Daily Living (ADL), and Instrumental Activities of Daily Living (IADL)

155 ility to perform activities of daily living (ADL), in older patients with asymptomatic primary hyperp

156 Up and Go (GUG), Activities of Daily Living (ADL), Instrumental Activities in Daily Living (IADL), Mi

157 PDRS), scales of activities of daily living (ADL), neuropsychological testing, and PET imaging with 1

158 ed dependence in Activities of Daily Living (ADL), oral symptoms, and presence of a caregiver.

159 nual death rate, Activities of Daily Living (ADL), physical performance in three tests and cognitive

160 h three metrics: activities of daily living (ADL), the Braden Scale, and the Morse fall risk score.

161 on self-reported Activities of Daily Living (ADL).

162 (IADL) and basic activities of daily living (ADL).

163 and a survey of activities of daily living (ADL).

164 to perform basic activities of daily living (ADL).

165 Frailty, activities of daily living (ADL)/instrumental ADL (IADL) disability, Centers for Epi

166 or difficulty in activities of daily living (ADL; e.g., transferring).

167 , limitations in activities of daily living (ADLs) (ADLs and instrumental ADLs), emergency department

168 ne the number of activities of daily living (ADLs) and instrumental ADLs (IADLs) for which patients n

169 Activities of daily living (ADLs) and instrumental ADLs (IADLs) were evaluated throu

170 ard to mobility, activities of daily living (ADLs) and Modified Rankin Scale (MRS) score at admission

171 o limitations in activities of daily living (ADLs) at baseline, 697 remained ADL independent, 84 beca

172 atus survey of 5 activities of daily living (ADLs) at hospital admission and 3, 6, and 12 months post

173 ifficulty with 9 activities of daily living (ADLs) was assessed by a questionnaire.

174 ny disability in activities of daily living (ADLs), (2) any disability in instrumental ADLs but not i

175 remity function, activities of daily living (ADLs), and instrumental ADLs (IADLs) self-reported appro

176 ility to perform activities of daily living (ADLs), and quality of life (QOL).

177 lity to complete activities of daily living (ADLs), caregiver distress, cognitive safety (based on sc

178 Impairment in activities of daily living (ADLs), defined as self-reported difficulty performing 1

179 ed the effect of activities of daily living (ADLs), living conditions, occupational and recreational

180 ility to perform activities of daily living (ADLs), walk one-quarter mile, or lift 10 lbs.

181 d complete basic activities of daily living (ADLs).

182 mental and basic activities of daily living (ADLs); and emergency department (ED) visits not resultin

183 and instrumental activities of daily living (ADLs, IADLs), cognition (Mini-Cog test), history of fall

184 vere, persistent activities-of-daily-living (ADLs) disability, defined as dependence in >/=3 ADLs for

185 , functionality (activities of daily living [ADL] + instrumental activities of daily living [IADL]),

186 scale (measuring activities of daily living [ADLs] and instrumental ADLs).

187 In males, ADL sensory responses are diminished; in addition, a sec

188 mum data set-activities of daily living (MDS-ADL), respectively.

189 mum Data Set-Activities of Daily Living [MDS-ADL] scale of 0 to 28 points, with higher scores indicat

190 Mean MDS-ADL self-performance score worsened by 1.2 (0.6 to 1.8)

191 The median MDS-ADL score increased from 12 during the 3 months before t

192 ated by an increase of 2.8 points in the MDS-ADL score (95% confidence interval [CI], 2.5 to 3.0); th

193 uospatial ability (p=0.002), and for the MDS-ADL subitem locomotion on unit (p=0.021).

194 dose of study drug, had a valid baseline MG-ADL assessment, and at least one post-baseline MG-ADL as

195 ssessment, and at least one post-baseline MG-ADL assessment.

196 as the change from baseline to week 26 in MG-ADL total score measured by worst-rank ANCOVA.

197 thenia Gravis-Activities of Daily Living (MG-ADL) score of 6 or more, Myasthenia Gravis Foundation of

198 INTERPRETATION: The change in the MG-ADL score was not statistically significant between ecul

199 (59.4%) reported difficulty with one or more ADLs at enrollment, with 272 (24.1%) and 146 (12.9%) exp

200 elf-reported difficulty performing 1 or more ADLs, assessed every 2 years for a maximum follow-up of

201 Expression of unc-1(dn) in RMG hub neurons, ADL or ASK pheromone-sensing neurons, or URX oxygen-sens

202 758 participants ages > or =65 years with no ADL disability at baseline were included in the analyses

203 1.16, 5389.92, 7526.38, and 3752.74 km(2) of ADL in the above 4 periods, accounting for 28.56%, 39.06

204 The associations of ADL difficulty with mortality and hospitalization were a

205 Almost 1 in every 4 new cases of ADL disability was due to arthritis (adjusted population

206 Patients were divided into 3 categories of ADL difficulty (no/minimal, moderate, severe).

207 We studied the effects of ADL 8-2698, an investigational opioid antagonist with li

208 Each additional hour of ADL (90 days) decreased the likelihood of SROP by 28% (P

209 yes developing SROP, each additional hour of ADL during the first 105 days after the EDC decreased th

210 itis had a substantially higher incidence of ADL disability compared with those without arthritis (9.

211 ffect was associated with lower incidence of ADL disability in older Mexican Americans with self-repo

212 Patients given 6 mg of ADL 8-2698 had significantly faster recovery of gastroin

213 ceive one capsule containing 1 mg or 6 mg of ADL 8-2698 or an identical-appearing placebo capsule two

214 Effects in the group that received 1 mg of ADL 8-2698 were less pronounced.

215 an [95% confidence interval [CI]] numbers of ADL dependencies: 0.69 [0.19-1.19] at 12 months before d

216 This was because the odds of ADL impairment did not change for obese individuals but

217 addition, Hispanics reported higher rates of ADL limitations than did non-Hispanic whites with compar

218 t having a larger effect in reducing risk of ADL dependence in men than in women.

219 tive affect (score = 12) and reduced risk of ADL disability 2 years later, controlling for baseline s

220 R 1.37, 0.90-1.91); indeed a reduced risk of ADL impairment appeared after multivariable adjustment (

221 s toxin light chain, separating the roles of ADL electrical and chemical synapses.

222 ls of H2O2 induced a massive accumulation of ADLs.

223 ent in the hospital focused on evaluation of ADLs, mobility, and cognition.

224 cells correlated well with the formation of ADLs.

225 The number of ADLs and instrumental ADLs (range, 0-12) that the partic

226 interval [CI], 0.6-2.6) or in the number of ADLs recovered to premorbid level (difference, 0.09 ADL;

227 ional capacity, and hence the performance of ADLs in asymptomatic, older PHPT patients.

228 and there were no differences in recovery of ADLs for either condition.

229 trongly prognostic for functional decline on ADL and IADL, and G8, fTRST (1), and fTRST (2) were prog

230 holinesterase inhibitors improved 0.1 SDs on ADL scales (95% CI, 0.00-0.19 SDs), and 0.09 SDs on IADL

231 on depending on its expression in the ASJ or ADL sensory neurons, respectively.

232 a significant difference in ICARS, FARS, or ADL total scores, there were indications of a dose-depen

233 myalgia differed significantly in their pain:ADL ratios, in both languages.

234 1.6; 95% confidence interval 1.05, 2.57, per ADL-L quartile) were independently associated with incre

235 ted pain, ambulation, and ability to perform ADL before and after vertebroplasty were evaluated with

236 Ability to perform ADL was also significantly improved following vertebropl

237 e, and 14.6% died without severe, persistent ADL dependence in the derivation cohort (n = 8,301); the

238 g 5 years, 6.8% developed severe, persistent ADL dependence, and 14.6% died without severe, persisten

239 Here we show that H2O2 produces ADLs at concentrations as low as 0.06 mM in HeLa cells a

240 sity were associated with new or progressive ADL and IADL disability in a dose-dependent manner, part

241 justed OR, 3.3; 95% CI, 1.5-7.2) and recover ADLs (difference, 0.63 ADL; 95% CI, 0.20-1.07).

242 aily living (ADLs) at baseline, 697 remained ADL independent, 84 became ADL dependent, 41 died, and 1

243 on and conflicting evidence on self-reported ADL (changes ranged from -1.38% to 1.53% per year) and v

244 synaptic activity between the ascr#3-sensing ADL neurons and their post-synaptic SMB motor neuron par

245 on remained stable for functional and severe ADL impairment and decreased for moderate-to-severe ADL

246 airment and decreased for moderate-to-severe ADL impairment.

247 to shop for personal items was the specific ADL more commonly retained by the GC group compared with

248 cores but not on the NPI agitation subscale, ADLs, or in less use of rescue lorazepam.

249 s (self reported) on incidence of subsequent ADL disability after controlling for baseline difference

250 Stratification by age indicated that ADLs were most strongly associated with mortality in the

251 These results suggest that ADLs induced by submillimolar levels of H2O2 may be due

252 The ADL development in north Shanxi was a result of mutual i

253 The ADL sensory neurons detect C9 and, in wild-type hermaphr

254 bilitation hospital is predicted by both the ADL (<12) and Braden Scale (<16), with respective adjust

255 scr#10 requires TRPV channel function in the ADL neurons and the daf-7 signaling from the ASI neurons

256 s were observed for 18.1% of patients on the ADL, 73.0% of patients on the IADL, 24.1% of patients on

257 directs expression of reporter genes to the ADL chemosensory neurons.

258 deterioration of ataxia symptoms over time; ADL is an appropriate measure to monitor changes in dail

259 ity is an independent factor contributing to ADL disability in these populations and should be includ

260 With respect to ADL impairment, odds for obese individuals were not sign

261 For functional outcomes, 14 trials used ADL and 13 trials used IADL scales.

262 Time windows when ADL was most closely associated with SROP were 31 to 60

263 limitation at baseline, including 12.9% with ADL limitations.

264 CIRS-G grade 3/4 had a fair correlation with ADL (p = 0.27).

265 Correlation of ECOG PS with ADL (p = 0.51)c and IADL (p = 0.61) was moderate.

266 % of survivors reported more difficulty with ADLs and patients with persistently severe or worsening

267 s more likely to have severe difficulty with ADLs, walking, or lifting at baseline compared with wome

268 at baseline, 17% developed new or worsening ADL disability and 26% developed new or worsening IADL d